Final Announcement:

Impact of COVID-19 on clinical trials

Wednesday May 6, 2020, 10-12 am

Virtual Seminar

The COVID-19 pandemic hits not only societies around the world hard but also clinical trials. Trials are affected to a different degree, depending on the indication, site location, and trial stage. For some trials, the impact can be substantial. Therefore, it is time to talk about this impact and mitigation steps.

This will be the first virtual seminar organized by the BBS, so it is a bit of an experiment still, especially for the panel discussion. Further virtual events on COVID-19 and other topics are planned in the near future.

Program

| 10:00-10:05 | Welcome Hans Ulrich Burger, BBS president |
|-------------|---|
| 10:05-10:35 | EMA perspective and guidance on COVID-19 |
| | Frank Pétavy, EMA |
| 10:35-11:20 | Industry perspective on COVID-19 |
| | Natalie Dimier, Roche Mouna Akacha, Novartis Cristina Sotto, J&J |
| 11:20-11:30 | Short Overview of Pharmaceutical Industry COVID-19 Biostatistics Working Group Marcel Wolbers, Roche |
| 11:30-11:40 | Short overview on COVID-19 from the Cross-Industry Oncology Estimands Working Group Evgeny Degtyarev, Novartis |
| 11:40-12:00 | Panel Discussion All presenters |
| 12:00 | Closure of the meeting Hans Ulrich Burger, BBS president |



Venue

Virtual event

Registration

Please register via e-mail to Laurence Guillier laurence.guillier@roche.com

Questions for the Panel discussion

Please send questions for the panel discussion to Hans Ulrich Burger hans ulrich.burger@roche.com